AVEO Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 15.17 million compared to USD 3.6 million a year ago. Net loss was USD 10.37 million compared to USD 8.39 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.33 a year ago. For the nine months, revenue was USD 24.65 million compared to USD 5.13 million a year ago. Net loss was USD 46.09 million compared to USD 24.08 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.22 a year ago.